ArticleInflammatory bowel diseases2026
OCTN1 variants shape innate immunity and predict individual response to anti-TNFα in ulcerative colitis patients: An exploratory study.
Article in Inflammatory bowel diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundUlcerative colitis (UC) exhibits substantial heterogeneity in inflammatory pathways and therapeutic response. The organic cation transporter OCTN1 (SLC22A4) and its rs1050152 missense variant (L503F) have been implicated in innate immune activation and disease susceptibility. We investigated whether OCTN1 variants modulate monocyte inflammatory responses and predict clinical outcomes in UC patients treated with anti-tumor necrosis factor α (TNFα) agents.
methodsWe combined preclinical and clinical approaches. In THP-1 cells engineered for OCTN1 knockdown or variant-specific overexpression, and in primary monocytes isolated from genotyped donors and UC patients, we assessed by enzyme-linked immunosorbent assay and Western blot interleukin (IL)-1β production following bacterial stimulation (peptidoglycan, Fusobacterium nucleatum, Escherichia coli, Salmonella). In the clinical study, UC patients initiating anti-TNFα therapy were genotyped and evaluated for 1-year therapy persistence, steroid-free clinical remission, and endoscopic response. Logistic regression models were used to identify predictors of outcomes. An exploratory machine learning analysis (regularized logistic regression and neural networks) was performed to rank the variables contributing to each endpoint.
resultsOCTN1-deficient THP-1 cells showed markedly reduced interleukin-1β secretion, whereas the same cell line or primary monocytes carrying the 503F variant exhibited significantly enhanced cytokine release upon microbial stimulation. On the clinical side, 105 patients with UC were enrolled. The homozygous 503F genotype (TT) was strongly associated with higher rates of steroid-free remission, endoscopic response, and therapy persistence. Heterozygous carriers displayed intermediate outcomes. Machine learning models demonstrated moderate predictive performance (area under the curve 0.60-0.72), consistently ranking OCTN1 among relevant, though not dominant, determinants of therapeutic success.
conclusionsThe OCTN1 503F variant enhances interleukin-1β-mediated innate immune activation and is associated with improved long-term response to anti-TNFα therapy in UC. These findings support OCTN1 genotyping as a promising component of future precision medicine strategies in inflammatory bowel disease and warrant confirmation in larger prospective multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.